[HTML][HTML] Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter”
The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of
malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for …
malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for …
[HTML][HTML] miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
…, K Grillone, C Riillo, G Caridà, F Scionti… - … Therapy-Nucleic Acids, 2022 - cell.com
Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely
investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence …
investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence …
[HTML][HTML] miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy
Simple Summary Cancer onset and progression are promoted by high deregulation of the
immune system. Recently, major advances in molecular and clinical cancer immunology have …
immune system. Recently, major advances in molecular and clinical cancer immunology have …
[HTML][HTML] Advances in Alport syndrome diagnosis using next-generation sequencing
R Artuso, C Fallerini, L Dosa, F Scionti… - European Journal of …, 2012 - nature.com
Alport syndrome (ATS) is a hereditary nephropathy often associated with sensorineural
hypoacusis and ocular abnormalities. Mutations in the COL4A5 gene cause X-linked ATS. …
hypoacusis and ocular abnormalities. Mutations in the COL4A5 gene cause X-linked ATS. …
[HTML][HTML] Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: A first-in-human, phase 1 …
…, N Staropoli, D Ciliberto, A Cordua, F Scionti… - Journal of Hematology & …, 2023 - Springer
Background We developed a 13-mer locked nucleic acid (LNA) inhibitor of miR-221 (LNA-i-miR-221)
with a full phosphorothioate (PS)-modified backbone. This agent downregulated …
with a full phosphorothioate (PS)-modified backbone. This agent downregulated …
[HTML][HTML] The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma
…, R Rocca, S Ascrizzi, V Spanò, F Scionti… - International Journal of …, 2022 - mdpi.com
Microtubule-targeting agents (MTAs) are effective drugs for cancer treatment. A novel diaryl [1,2]oxazole
class of compounds binding the colchicine site was synthesized as cis-restricted…
class of compounds binding the colchicine site was synthesized as cis-restricted…
Pharmacogenomics biomarker discovery and validation for translation in clinical practice
M Arbitrio, F Scionti, MT Di Martino… - Clinical and …, 2021 - Wiley Online Library
Interindividual variability in drug efficacy and toxicity is a major challenge in clinical practice.
Variations in drug pharmacokinetics (PKs) and pharmacodynamics (PDs) can be, in part, …
Variations in drug pharmacokinetics (PKs) and pharmacodynamics (PDs) can be, in part, …
[HTML][HTML] DMET™(Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
In the era of personalized medicine, high-throughput technologies have allowed the investigation
of genetic variations underlying the inter-individual variability in drug pharmacokinetics/…
of genetic variations underlying the inter-individual variability in drug pharmacokinetics/…
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis
Purpose Erlotinib is a targeted agent commonly used in advanced non-small cell lung cancer
(aNSCLC). However, drug-related skin toxicity often may affect the quality of life of cancer …
(aNSCLC). However, drug-related skin toxicity often may affect the quality of life of cancer …
Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
…, M Ragusa, MT Di Martino, F Scionti… - Liver …, 2019 - Wiley Online Library
Background & Aims In patients with non‐alcoholic fatty liver disease (NAFLD), liver biopsy
is the gold standard to detect non‐alcoholic steatohepatitis (NASH) and stage liver fibrosis. …
is the gold standard to detect non‐alcoholic steatohepatitis (NASH) and stage liver fibrosis. …